Literature DB >> 26662570

Impact of IGF-1, IGF-1R, and IGFBP-3 promoter methylation on the risk and prognosis of esophageal carcinoma.

Peng Ye1, Chang-Fa Qu2, Xue-Lin Hu3.   

Abstract

The aim of this study is to investigate IGF-1, IGF-1R, and IGFBP-3 methylations in esophageal carcinoma (EC) patients and their relationship with the development and prognosis of EC. This study population consisted of 264 patients (case group) whom EC radical resection was performed and 283 healthy individuals (control group). Methylation-specific PCR (MSP) detected the methylation status of IGF-1, IGF-1R, and IGFBP-3 in the peripheral blood in both groups. The expressions of IGF-1, IGF-1R, and IGFBP-3 in EC and adjacent normal tissues were detected by immunohistochemistry (IHC). The methylation rates of IGF-1, IGF-1R, IGFBP3, and IGF-1 + IGF1R + IGFBP3 in the case group were higher than those in the control group (all P < 0.05). Additionally, there were statistical significances for the methylation rates of IGF-1, IGF-1R, IGFBP3, and IGF-1 + IGF1R + IGFBP3 IGF-1 among patients of different clinicopathological features (all P < 0.05). The positive expression rates of IGF-1 and IGF-1R in EC were significantly higher than those in adjacent normal tissues (both P < 0.001), and the rate of IGFBP-3 in EC was significantly lower than that in adjacent normal tissues (P < 0.05). Correlation analysis showed that IGF-1 and IGF1R gene promoter methylation was positively correlated with the positive expressions of IGF-1 (r = 0.139, P = 0.024) and IGF-1R (r = 0.135, P = 0.028), while the IGFBP3 methylation was negatively correlated with the positive expression of IGFBP3 (r = -0.133, P = 0.031). The positive expressions of IGF-1, IGF-1R, and IGFBP-3 were related to different clinicopathological features (all P < 0.05). Cox multivariate analysis results showed that methylation status of IGF-1, IGF-1R, and IGF-1 + IGF1R + IGFBP3 ; expressions of IGF-1 and IGF-1R protein; infiltration depth; and lymph node metastasis (LNM) were independent factors of EC prognosis. Our study demonstrated that methylation of IGF-1, IGF1R, IGFBP3, and IGF-1 + IGF1R + IGFBP3 was closely linked with the occurrence of EC and patients' clinicopathological features. Besides, the methylation status of the target genes and the expressions of IGF-1 and IGF-1R protein were independent factors of EC prognosis, which could provide a direction for the prognosis and treatment of EC.

Entities:  

Keywords:  Clinicopathological features; Esophageal carcinoma; IGF-1; IGF-1R; IGFBP-3; Methylation; Prognosis

Mesh:

Substances:

Year:  2015        PMID: 26662570     DOI: 10.1007/s13277-015-4489-5

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  34 in total

1.  Targeting the insulin-like growth factor receptor-1R pathway for cancer therapy.

Authors:  Jiping Zha; Mark R Lackner
Journal:  Clin Cancer Res       Date:  2010-04-13       Impact factor: 12.531

2.  IGF2 is an actionable target that identifies a distinct subpopulation of colorectal cancer patients with marginal response to anti-EGFR therapies.

Authors:  Eugenia R Zanella; Francesco Galimi; Francesco Sassi; Giorgia Migliardi; Francesca Cottino; Simonetta M Leto; Barbara Lupo; Jessica Erriquez; Claudio Isella; Paolo M Comoglio; Enzo Medico; Sabine Tejpar; Eva Budinská; Livio Trusolino; Andrea Bertotti
Journal:  Sci Transl Med       Date:  2015-01-28       Impact factor: 17.956

3.  Methylation profiling of 48 candidate genes in tumor and matched normal tissues from breast cancer patients.

Authors:  Zibo Li; Xinwu Guo; Yepeng Wu; Shengyun Li; Jinhua Yan; Limin Peng; Zhi Xiao; Shouman Wang; Zhongping Deng; Lizhong Dai; Wenjun Yi; Kun Xia; Lili Tang; Jun Wang
Journal:  Breast Cancer Res Treat       Date:  2015-01-31       Impact factor: 4.872

4.  [Difference in methylation of genomic DNA between gastric primary cancer and lymph nodes with metastatic gastric cancer].

Authors:  Jian-feng Wang; Dong-qiu Dai
Journal:  Zhonghua Yi Xue Za Zhi       Date:  2006-02-28

5.  Salidroside Mitigates Sepsis-Induced Myocarditis in Rats by Regulating IGF-1/PI3K/Akt/GSK-3β Signaling.

Authors:  He He; Xiayun Chang; Jin Gao; Lingpeng Zhu; Mingxing Miao; Tianhua Yan
Journal:  Inflammation       Date:  2015-12       Impact factor: 4.092

6.  TGF-β-induced expression of IGFBP-3 regulates IGF1R signaling in human osteosarcoma cells.

Authors:  Lynette J Schedlich; Vanessa M Yenson; Robert C Baxter
Journal:  Mol Cell Endocrinol       Date:  2013-07-02       Impact factor: 4.102

7.  IGFBP-3 can either inhibit or enhance EGF-mediated growth of breast epithelial cells dependent upon the presence of fibronectin.

Authors:  Jamie McIntosh; Godwin Dennison; Jeff M P Holly; Caroline Jarrett; Alexandra Frankow; Emily J Foulstone; Zoe E Winters; Claire M Perks
Journal:  J Biol Chem       Date:  2010-09-17       Impact factor: 5.157

8.  Insulin-like growth factor binding protein-3 (IGFBP-3) plays a role in the anti-tumorigenic effects of 5-Aza-2'-deoxycytidine (AZA) in breast cancer cells.

Authors:  Li Zeng; Caroline Jarrett; Keith Brown; Kathleen M Gillespie; Jeff M P Holly; Claire M Perks
Journal:  Exp Cell Res       Date:  2013-06-26       Impact factor: 3.905

9.  IGFBP3 impedes aggressive growth of pediatric liver cancer and is epigenetically silenced in vascular invasive and metastatic tumors.

Authors:  Ivonne Regel; Melanie Eichenmüller; Saskia Joppien; Johanna Liebl; Beate Häberle; Josef Müller-Höcker; Angelika Vollmar; Dietrich von Schweinitz; Roland Kappler
Journal:  Mol Cancer       Date:  2012-03-08       Impact factor: 27.401

10.  Methylation status of IGFBP-3 as a useful clinical tool for deciding on a concomitant radiotherapy.

Authors:  Olga Pernía; Cristobal Belda-Iniesta; Veronica Pulido; María Cortes-Sempere; Carlos Rodriguez; Olga Vera; Javier Soto; Julia Jiménez; Alvaro Taus; Federico Rojo; Edurne Arriola; Ana Rovira; Joan Albanell; M Teresa Macías; Javier de Castro; Rosario Perona; Inmaculada Ibañez de Caceres
Journal:  Epigenetics       Date:  2014-11       Impact factor: 4.528

View more
  6 in total

1.  The low IGFBP-3 level is associated with esophageal cancer patients: a meta-analysis.

Authors:  Guiqin Song; Kang Liu; Xiaoyan Zhu; Xiaolin Yang; Yuewu Shen; Wan Wang; Guidong Shi; Qing Li; Yi Duan; Yunxia Zhao; Gang Feng
Journal:  World J Surg Oncol       Date:  2016-12-15       Impact factor: 2.754

2.  Effects and Mechanisms of Metformin on the Proliferation of Esophageal Cancer Cells In Vitro and In Vivo.

Authors:  Jian-Cai Tang; Rui An; Yi-Qing Jiang; Jian Yang
Journal:  Cancer Res Treat       Date:  2016-11-11       Impact factor: 4.679

3.  Overcoming Linsitinib intrinsic resistance through inhibition of nuclear factor-κB signaling in esophageal squamous cell carcinoma.

Authors:  Junzhou Wu; Kaiyan Chen; Fanrong Zhang; Jiaoyue Jin; Nan Zhang; Dan Li; Lisha Ying; Wei Chen; Herbert Yu; Weimin Mao; Dan Su
Journal:  Cancer Med       Date:  2017-04-24       Impact factor: 4.452

4.  Integrated bioinformatics analysis to decipher molecular mechanism of compound Kushen injection for esophageal cancer by combining WGCNA with network pharmacology.

Authors:  Wei Zhou; Jiarui Wu; Jingyuan Zhang; Xinkui Liu; Siyu Guo; ShanShan Jia; Xiaomeng Zhang; Yingli Zhu; Miaomiao Wang
Journal:  Sci Rep       Date:  2020-07-29       Impact factor: 4.379

5.  Gene promoter and exon DNA methylation changes in colon cancer development - mRNA expression and tumor mutation alterations.

Authors:  Béla Molnár; Orsolya Galamb; Bálint Péterfia; Barnabás Wichmann; István Csabai; András Bodor; Alexandra Kalmár; Krisztina Andrea Szigeti; Barbara Kinga Barták; Zsófia Brigitta Nagy; Gábor Valcz; Árpád V Patai; Péter Igaz; Zsolt Tulassay
Journal:  BMC Cancer       Date:  2018-06-27       Impact factor: 4.430

6.  Serum insulin-like growth factor binding protein-3 as a potential biomarker for diagnosis and prognosis of oesophageal squamous cell carcinoma.

Authors:  Yun Luo; Chao-Qun Hong; Bin-Liang Huang; Tian-Yan Ding; Ling-Yu Chu; Biao Zhang; Qi-Qi Qu; Xin-Hao Li; Can-Tong Liu; Yu-Hui Peng; Hai-Peng Guo; Yi-Wei Xu
Journal:  Ann Med       Date:  2022-12       Impact factor: 5.348

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.